REG - Oxford Biomedica PLC - Person Closely Associated Dealing

Oxford BioMedicaAnnouncement

27/06/2024 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240627:nRSa2002Ua&default-theme=true

RNS Number : 2002U  Oxford Biomedica PLC  27 June 2024

 

 

Person Closely Associated Dealing

 

Oxford, UK - 27 June 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a quality and innovation-led cell and gene
therapy CDMO, today announces that Pippa Radcliffe, a person closely
associated with Kyriacos Mitrophanous, Chief Innovation Officer of the
Company, exercised 839 options at nil cost and disposed 274 shares at £3 per
share on 25 June 2024.

 

The below notification, made in accordance with the requirements of the EU
Market Abuse Regulation, give further details of the transaction.

 

 1.  Details of the Person Closely Associated ("PCA")
 a)  Name                                     Pippa Radcliffe
 2.  Reason for the notification
 a)  Position/status                          This notification concerns Pippa Radcliffe in her capacity as a person closely
                                              associated with a person discharging managerial responsibilities. The person
                                              discharging managerial responsibilities is Kyriacos Mitrophanous, Chief
                                              Innovation Officer of the Company. The association arises by virtue of Pippa
                                              Radcliffe being the spouse of Kyriacos Mitrophanous.

 b)  Initial notification/                    Initial Notification/Amendment

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Exercise of Options at nil cost
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              Nil       839

 e)  Aggregated information

     -    Aggregate volume                    839

     -    Price

     -    Aggregated total                    NIL

                                              NIL
 f)  Date of the transaction                  2024-06-25
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

e)

Aggregated information

-    Aggregate volume

-    Price

-    Aggregated total

 

 

839

 

NIL

NIL

f)

Date of the transaction

2024-06-25

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")/person
     closely associated with them ("PCA")
 a)  Name                                     Pippa Radcliffe
 2.  Reason for the notification
 a)  Position/status                          This notification concerns Pippa Radcliffe in her capacity as a person closely
                                              associated with a person discharging managerial responsibilities. The person
                                              discharging managerial responsibilities is Kyriacos Mitrophanous, Chief
                                              Innovation Officer of the Company. The association arises by virtue of Pippa
                                              Radcliffe being the spouse of Kyriacos Mitrophanous.

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford BioMedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code                      ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Disposal
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £3        274

 

 e)  Aggregated information

     -    Aggregate volume                    274

     -    Price

                                              £3

     -    Aggregated total

                                              £822.00
 f)  Date of the transaction                  2024-06-25
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

 

 

e)

Aggregated information

-    Aggregate volume

 

-    Price

 

-    Aggregated total

 

 

274

 

 

£3

 

£822.00

f)

Date of the transaction

2024-06-25

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

ABOUT OXFORD BIOMEDICA

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract
development and manufacturing organisation (CDMO) in cell and gene therapy
with a mission to enable its clients to deliver life changing therapies to
patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has more than 25
years of experience in viral vectors; the driving force behind the majority of
cell and gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus, adeno-associated virus
(AAV), adenovirus, and other viral vector types. Oxford Biomedica's
world-class capabilities span from early-stage development to
commercialisation. These capabilities are supported by robust
quality-assurance systems, analytical methods and depth of regulatory
expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon
and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com
(https://www.oxb.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFEFRVIDFIS